In high-dose immediate-release tablet production, sulpiride pharma grade is typically processed by high-shear wet granulation rather than direct compression when the dose exceeds 200 mg per unit. The as-received API exhibits poor flow and high bulk-volume variability; preblending with 15–25% w/w microcrystalline cellulose and 5–10% w/w pregelatinized starch compensates for these attributes but does not eliminate segregation risk in a direct-compression feeder. A typical core for a 200 mg strength tablet is 350 mg, giving an API fraction of 57.1% w/w; the wider commercial range is 50–65% w/w depending on excipient grade and tablet weight. Granulation is performed in a high-shear mixer at impeller speed 250–350 rpm and chopper speed 1500–2500 rpm, with purified water added at 20–25% w/w until wet-mass endpoint torque reaches a defined target. The wet granules are dried in a fluid-bed dryer with inlet air temperature 55–65°C to a final loss-on-drying of 1.5–2.5%, then milled through a 0.8 mm conical screen. Lubrication with magnesium stearate at 0.5–1.0% w/w is carried out in a bin blender for 3–5 min to avoid overlubrication, which lowers tablet tensile strength.

Compression is performed on a rotary tablet press equipped with 10 mm round punches and a compression force of 16–24 kN, producing cores with hardness 80–120 N and friability below 1.0% when tested according to Ph. Eur. 2.9.7. Disintegration is controlled to below <15 min in 0.1 M HCl at 37±0.5°C using the apparatus of Ph. Eur. 2.9.1. Aqueous film coating with hypromellose-based Opadry II is applied at 12–15% w/w solids, inlet air temperature 60–70°C, and pan speed 4–6 rpm until a weight gain of 2.5–3.5% w/w is achieved. The finished product is a film-coated immediate-release tablet supplied in 50 mg, 200 mg, and 400 mg strengths. Batch processing is constrained by relative humidity: granule transfer and compression should occur below 60% RH because sulpiride uptake of surface moisture above this threshold measurably shifts weight variation and lowers granule flow. Compliance is governed by the Ph. Eur. monograph for Sulpiride, ICH Q3D elemental impurities, ICH M7 mutagenic impurities, and EU GMP Part II for APIs.

When is capsule filling preferred over high-dose tablet compression for sulpiride dose titration?

For 50 mg capsule-based dose titration, the API is first passed through a 0.5 mm sieve and then geometrically diluted with lactose monohydrate in a tumble blender at 15–20 rpm for 20 min. The capsule fill weight is commonly 180 mg for a size 3 hard gelatin capsule, yielding an API fraction of 27.8% w/w; the operational range is 25–45% w/w when higher fill weights are used to improve flow. Powder filling is performed on a dosator-type capsule filler, because the tamping-pin alternative can generate higher dusting with low-density sulpiride blends. Weight variation is maintained within ±7.5% for fills below 300 mg according to Ph. Eur. 2.9.5, and content uniformity is tested by Ph. Eur. 2.9.40. Dissolution is evaluated with apparatus 2 paddle at 50 rpm in a medium defined by the current sulpiride monograph; the acceptance criterion is stage S1 or S2 as per USP <711>.

The terminal product is a hard gelatin capsule for oral administration, typically 50 mg strength, used for low-dose initiation and dose adjustment in psychiatric therapy. The process is constrained by capsule shell brittleness below 40% RH and softening above 55% RH; filling rooms are therefore maintained at 45–50% RH and 20–25°C. Excipient compatibility is monitored because magnesium stearate at above 1.0% w/w can retard dissolution of the hydrophobic sulpiride surface. Batch records include ICH Q3D elemental impurity testing and residual solvent analysis according to Ph. Eur. 5.4. Where dose uniformity failures occur, the root cause is usually particle-size segregation of the micronized API; laser diffraction analysis of the blend with a D90 target of ≤90 µm is used as a release gate. No direct correlation between capsule shell cross-linking and sulpiride degradation has been observed under accelerated conditions at 40°C/75% RH for 6 months.

If dose flexibility in psychosomatic treatment requires granule-based administration

Granule-based sulpiride products are manufactured as unit-dose sachets for oral solution, with a typical sachet containing 25 mg sulpiride in a 500 mg granule bed, equivalent to 5.0% w/w. Sugar spheres or sucrose granules are not used as the primary substrate; instead, a wet granulate of sucrose, mannitol, citric acid, sodium citrate, and sodium carboxymethylcellulose is formed in a fluid-bed top-spray granulator at inlet air temperature 60–70°C and atomization pressure 1.5–2.0 bar. API is added as a micronized suspension in purified water, not as dry powder, to reduce content uniformity failures; the suspension is continuously stirred to prevent sedimentation and passed through a 0.5 mm in-line screen. Final granule moisture is controlled at 1.5–2.5% and particle size is verified by sieve analysis according to Ph. Eur. 2.9.12; the fraction below 125 µm is limited to below 15% to avoid dusting during sachet filling.

Vertical form-fill-seal machines fill the granules into laminate sachets at 25–30°C and below 40% RH; seal integrity is tested by vacuum decay per ASTM F2338-09 or equivalent. The terminal product type is granules for oral solution, prepared by emptying a sachet into water. Dissolution performance of the granule dosage form is evaluated by Ph. Eur. 2.9.3 after reconstitution; compliance with ICH Q3D, Ph. Eur. 5.4, and the current sulpiride monograph is required. Storage stability is the main limitation: the acidulant and flavor system can promote moisture uptake, so sachets are packed with desiccant if the product is distributed in ICH climatic zone IVb conditions. Batch-to-batch variance in flow, measured by Carr index calculated from bulk and tapped density per Ph. Eur. 2.9.34, is kept below 20% to ensure sachet fill accuracy.

Injectable dosage forms impose sterility and particulate limits that dominate process design before API content is considered. Sulpiride is formulated as a 50 mg/mL solution in 2 mL amber glass ampoules, giving 100 mg per ampoule and an API fraction of 5.0% w/v. Water for injection is heated to 35–40°C and the API is dissolved under low-speed stirring; sodium chloride is added to approach isotonicity, and pH is adjusted to 5.0–6.5 with dilute hydrochloric acid or sodium hydroxide. The bulk solution is passed through a 0.22 µm polyethersulfone filter and filled into depyrogenated glass ampoules under Grade A laminar airflow equivalent to ISO 14644-1:2015 Class 5 within a Grade B background, as specified by EU GMP Annex 1. Terminal moist-heat sterilization at 121°C for 15 min is selected when stability data demonstrate no assay loss; otherwise aseptic filtration is the default. Published data for this specific configuration is limited; manufacturers should verify heat-stress stability at the target pH before fixing the sterilization cycle.

Quality release includes sterility per Ph. Eur. 2.6.1, bacterial endotoxins per Ph. Eur. 2.6.14 with a limit derived from the maximum bolus dose by Ph. Eur. 5.1.10, sub-visible particles per Ph. Eur. 2.9.19, visible particles per Ph. Eur. 2.9.20, and uniformity of dosage units per Ph. Eur. 2.9.5. The terminal product is an injectable solution for intramuscular administration. Process constraints include oxygen control: ampoules are purged with nitrogen before sealing to keep dissolved oxygen below 2 mg/L; terminal sterilization and stability data define the acceptable oxygen ceiling. Cleaning validation for multi-product injectable lines follows ICH Q7 and EU GMP Annex 15, with acceptance limits based on permitted daily exposure. The API supplier must provide endotoxin and bioburden data for the non-sterile API because terminal sterilization cannot correct excessive pyrogen load.